Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013326 | 0.96 | — | — | |
| SCHEMBL12328299 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL5461992 | 0.92 | TSHR (0.40) | TSHRTDP1ALDH1A1 | |
| SCHEMBL4221722 | 0.79 | TSHR (0.50) | TSHRTDP1ALDH1A1 | |
| Bromide SCHEMBL1566230 | 0.75 | — | — | |
| SCHEMBL15081070 | 0.74 | — | — | |
| Bromide SCHEMBL28614626 | 0.72 | — | — | |
| Bromide SCHEMBL1705766 | 0.72 | — | — | |
| Bromide SCHEMBL28614336 | 0.72 | — | — | |
| SCHEMBL93450 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1199303-B1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6784321-B2 | 1-((2-ARYLSULFONYL)(3-METHYL)(5-OXY)PENT-3-ENE)-2,6,6-TRIMETHY LCYCLOHEX-1-ENE DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20040082814-A1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-04-29 | — | — | US | disclosed |
| US-20040034257-A1 | Novel sulfone derivatives and process for producing these | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6660888-B2 | A disulfone compound of given formula | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1359143-A1 | NOVEL SULFONE DERIVATIVES AND PROCESS FOR PRODUCING THESE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-20020058844-A1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6388124-B2 | CHEMICAL INTERMEDIATE FOR VITAMIN A ACETATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-1199303-A1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-20010025127-A1 | Dihalo-compound and process for producing vitamin A derivative | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2001-09-27 | — | — | US | disclosed |
| EP-1120398-A2 | Dihalo-compound and process for producing vitamin A derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082814-A1 | Process for producing retinol and intermediate compounds for producing the same | ADH4, ADH1B, ADH7 | TSHR 702/4885TDP1 4492/4885ALDH1A1 24/4885 |
| US-20040034257-A1 | Novel sulfone derivatives and process for producing these | RBP4, ADH4, RARB | TSHR 1488/4885TDP1 4862/4885ALDH1A1 323/4885 |
| US-20020058844-A1 | Process for producing retinol and intermediate compounds for producing the same | ADH4, ADH1B, ADH7 | TSHR 702/4885TDP1 4492/4885ALDH1A1 24/4885 |
| US-20010025127-A1 | Dihalo-compound and process for producing vitamin A derivative | CYP2R1, CYP24A1, VDR | TSHR 684/4885TDP1 4632/4885ALDH1A1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.